UBS Group’s VYNE Therapeutics VYNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
Sell
-7,576
Closed -$12K 9382
2025
Q1
$12K Buy
7,576
+6,945
+1,101% +$11K ﹤0.01% 7211
2024
Q4
$2.11K Buy
631
+617
+4,407% +$2.07K ﹤0.01% 7862
2024
Q3
$26 Sell
14
-25,044
-100% -$46.5K ﹤0.01% 8074
2024
Q2
$49.4K Buy
25,058
+25,042
+156,513% +$49.3K ﹤0.01% 5556
2024
Q1
$49 Sell
16
-830
-98% -$2.54K ﹤0.01% 7757
2023
Q4
$1.97K Buy
846
+662
+360% +$1.54K ﹤0.01% 6970
2023
Q3
$744 Sell
184
-902
-83% -$3.65K ﹤0.01% 7156
2023
Q2
$4.45K Buy
1,086
+721
+198% +$2.96K ﹤0.01% 6450
2023
Q1
$1.12K Sell
365
-2,672
-88% -$8.23K ﹤0.01% 7704
2022
Q4
$8.2K Buy
3,037
+2,456
+423% +$6.63K ﹤0.01% 7613
2022
Q3
$2K Sell
581
-1
-0.2% -$3 ﹤0.01% 8674
2022
Q2
$4K Buy
582
+568
+4,057% +$3.9K ﹤0.01% 8104
2022
Q1
$0 Hold
14
﹤0.01% 9660
2021
Q4
$0 Sell
14
-211
-94% ﹤0.01% 9432
2021
Q3
$6K Sell
225
-180
-44% -$4.8K ﹤0.01% 7304
2021
Q2
$26K Buy
405
+35
+9% +$2.25K ﹤0.01% 5996
2021
Q1
$46K Sell
370
-1,700
-82% -$211K ﹤0.01% 5642
2020
Q4
$236K Buy
2,070
+777
+60% +$88.6K ﹤0.01% 4182
2020
Q3
$155K Sell
1,293
-134
-9% -$16.1K ﹤0.01% 4124
2020
Q2
$178K Buy
1,427
+861
+152% +$107K ﹤0.01% 4086
2020
Q1
$109K Buy
566
+300
+113% +$57.8K ﹤0.01% 4368
2019
Q4
$89K Buy
266
+83
+45% +$27.8K ﹤0.01% 5030
2019
Q3
$59K Buy
183
+119
+186% +$38.4K ﹤0.01% 5170
2019
Q2
$28K Buy
64
+37
+137% +$16.2K ﹤0.01% 5519
2019
Q1
$15K Sell
27
-93
-78% -$51.7K ﹤0.01% 5718
2018
Q4
$36K Buy
+120
New +$36K ﹤0.01% 5450
2018
Q3
Sell
-11
Closed -$7K 7192
2018
Q2
$7K Buy
11
+6
+120% +$3.82K ﹤0.01% 6425
2018
Q1
$14K Buy
+5
New +$14K ﹤0.01% 5789